Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program
The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.
You may also be interested in...
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.